Immupharma PLC Corporate Update (8100S)
March 14 2019 - 3:01AM
UK Regulatory
TIDMIMM
RNS Number : 8100S
Immupharma PLC
14 March 2019
14 March 2019
ImmuPharma PLC
("ImmuPharma" or the "Company")
CORPORATE UPDATE
ImmuPharma PLC (LSE: IMM), the specialist drug discovery and
development company provides an update on ongoing activities.
Key highlights:
-- Lupuzor(TM)
o Lupuzor(TM) 'Managed Access Program'
o Phase III 'open label extension'
-- Nucant (cancer) program: Clinical development collaboration with Incanthera Limited
-- Urelix technology
Lupuzor(TM)
Lupuzor(TM) is the Company's late stage asset for Lupus, a
potential life threatening auto-immune disease. Following the
conclusion of the pivotal Phase III trial earlier in 2018,
ImmuPharma continues to look at opportunities which over the longer
term have the potential of bringing Lupuzor(TM) to market. As part
of this strategy, the Company continues to engage with potential
corporate partners as well as commencing a Managed Access Program
for Lupuzor(TM).
Lupuzor(TM) Managed Access Program
ImmuPharma, together with its partner, is in the final
preparations for its Managed Access Program ('MAP') being open to
eligible patients in Europe. Further updates will be provided to
the market in due course.
Lupuzor(TM) Extension Study
The Lupuzor(TM) open label extension study, from the original
Phase III trial, with a total of 62 eligible patients recruited
throughout the US and Europe, remains on track to report results in
Q2 2019.
Nucant Cancer Programme - Clinical Development Collaboration
As announced on 31 December 2018, the exclusivity period was
extended to 31 March 2019. Discussions continue on this
collaboration and an update will be provided in due course.
Ureka
ImmuPharma's subsidiary, Ureka Sarl ("Ureka") based in Bordeaux,
is focusing on transforming peptides into efficient drugs for
treatments in a number of therapeutic areas including Type II
diabetes and NASH (Non-Alcoholic-Steato-Hepatitis). Recently, a
fundamental research paper on Ureka' proprietary technology
'Urelix(TM)' was published in the peer reviewed research journal
'Nature Communications'.
ImmuPharma continues to look at all options regarding
progression of Ureka's assets. This process is ongoing and further
updates will be announced as appropriate.
Commenting on the announcement, Tim McCarthy, ImmuPharma's
Chairman said: "We remain focused on creating long term value
throughout our portfolio through initiatives including the Managed
Access Program for Lupuzor(TM), whilst the Company continues to
engage with industry partners for potential collaboration
opportunities on its projects."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014. ("MAR")
For further information please contact:
ImmuPharma plc (www.immupharma.com) + 44 (0) 207 152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 368 8974
Vassil Kirtchev
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDJJMLTMBABBTL
(END) Dow Jones Newswires
March 14, 2019 03:01 ET (07:01 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024